A Randomised Open-Label Phase II Trial of BI 6727 Monotherapy and BI 6727 in Combination With Standard Dose Pemetrexed Compared to Pemetrexed Monotherapy in Second Line Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Volasertib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 28 May 2014 Planned End Date changed from 1 May 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 25 Mar 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 30 Oct 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History